Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stan Sujka

Urology Orlando, FL Medical Doctor

NPI 1407844681 CMS profile 245625

41 W Kaley St, Orlando, FL 32806

Open in the dashboard

General payments

$7,708

341 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stan Sujka of Orlando, FL is reported in the CMS Open Payments database as having received $7,708 across 341 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23 1
2024 General $50 2
2023 General $1,170 56
2022 General $1,581 88
2021 General $1,256 69
2020 General $2,269 57
2019 General $1,358 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stan Sujka
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Stan Sujka were reported at $23. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Stan Sujka Urology median Middle half National median
2019 $1,358 $480 $147–$1,201 $163
2020 $2,269 $246 $87–$645 $114
2021 $1,256 $358 $111–$1,000 $132
2022 $1,581 $476 $143–$1,263 $149
2023 $1,170 $560 $168–$1,461 $160
2024 $50 $563 $170–$1,464 $164
2025 $23 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $2,108 61 payments
  2. Janssen Biotech, Inc. $897 44 payments
  3. Myriad Genetic Laboratories, Inc. $586 28 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $512 29 payments
  5. Coloplast Corp $422 15 payments
  6. Endo Pharmaceuticals Inc. $301 15 payments
  7. Dendreon Pharmaceuticals LLC $255 12 payments
  8. Pfizer Inc. $245 15 payments
  9. Allergan Inc. $217 10 payments
  10. Boston Scientific Corporation $185 8 payments
  11. Other $1,979 104 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,249 328 payments
  2. Consulting Fee $1,140 1 payment
  3. Education $319 12 payments
Products named General payments · program years 2019–2025
  1. XTANDI $1,876 49 payments
  2. ERLEADA $909 45 payments
  3. MYRBETRIQ $556 32 payments
  4. Nubeqa $512 29 payments
  5. AVEED $301 15 payments
  6. XIAFLEX $301 15 payments
  7. ORGOVYX $299 17 payments
  8. EDEX $258 13 payments
  9. PROVENGE $255 12 payments
  10. Prolaris $220 13 payments
  11. Other $3,340 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

269

Median for Urology: 1,053

Drug cost

$20,003

Median for Urology: $101,464

Branded share of claims

21.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 31 $15,884
Tamsulosin Hcl Generic 81 $1,368
Finasteride Generic 86 $1,056
Alfuzosin Hcl Er Alfuzosin Hcl Brand 28 $639
Dutasteride Generic 16 $619
Bicalutamide Generic 12 $318
Ciprofloxacin Hcl Generic 15 $119

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROVENGE
  • Dendreon Pharmaceuticals LLC $34
$34 — —
Trelstar
  • Verity Pharmaceuticals Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record